Changgong N. Zhang
Beijing Key Laboratory Of Key Technologies For Early Clinical Trial Evaluation Of Innovative Drugs For Major Diseases, Chinese Academy Of Medical Sciences & Peking Union Medical College
Beijing, China
Beijing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Safety, efficacy, and pharmacokinetics of eratrectinib (VC004) in solid tumors with NTRK fusions: phase 1 results from a phase 1/2 study.
Journal: Experimental hematology & oncology
Published: December 23, 2025
Association between invasive stratified mucinous carcinoma of the cervix and human papillomavirus genotypes
Journal: Zhonghua bing li xue za zhi = Chinese journal of pathology
Published: December 08, 2024
Efficacy, safety, and multi-omics analysis of pembrolizumab combined with nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous cell carcinoma: A single-arm phase 2 study.
Journal: Chinese journal of cancer research = Chung-kuo yen cheng yen chiu
Published: August 27, 2024
Deciphering the Prognostic Significance of MYD88 and CD79B Mutations in Diffuse Large B-Cell Lymphoma: Insights into Treatment Outcomes.
Journal: Targeted oncology
Published: March 15, 2024
Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial.
Journal: Cancer pathogenesis and therapy
Published: August 30, 2023
Efficacy and safety of PD-1 monoclonal antibody plus rituximab in relapsed/refractory diffuse large B cell lymphoma patients.
Journal: European journal of haematology
Published: April 04, 2023
MYD88L265P and MYD88other variants show different molecular characteristics and prognostic significance in diffuse large B-cell lymphoma.
Journal: Journal of cancer research and clinical oncology
Published: February 03, 2023
Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma.
Journal: Molecular diagnosis & therapy
Published: October 06, 2022
Clinical characteristics and treatment outcomes of Chinese diffuse large B-cell lymphoma patients in the era of rituximab (2005-2018).
Journal: Cancer pathogenesis and therapy
Published: July 07, 2022
Prognostic role of red blood cell distribution width and platelet/lymphocyte ratio in early-stage classical Hodgkin lymphoma.
Journal: Future oncology (London, England)
Published: February 18, 2022
Prognostic value of BCL2 and TP53 genetic alterations for diffuse large B-cell lymphoma patients treated with R-CHOP.
Journal: Cancer biology & medicine
Published: November 22, 2021
Last Updated: 09/26/2026